|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the STAA 10-K filed Mar 12, 2008. CompetitionCompetition in the ophthalmic surgical product market is intense and characterized by extensive research and development and rapid technological change. Development by competitors of new or improved products, processes or technologies may make our products obsolete or less competitive. Accordingly, we must devote continued efforts and significant financial resources to enhance our existing products and to develop new products for the ophthalmic industry. We believe our primary competitors in the development and sale of products used to surgically correct cataracts, specifically foldable IOLs, include Alcon Laboratories (“Alcon”), Advanced Medical Optics (“AMO”), and Bausch & Lomb. According to a 2007 Market Scope report, Alcon holds 55% of the U.S. IOL market, followed by AMO with 26% and Bausch & Lomb with 13%. We hold approximately 4% of the U.S. IOL market. Our competitors have been established for longer periods of time than we have and have significantly greater resources than we have, including greater name recognition, larger sales operations, greater ability to finance research and development and proceedings for regulatory approval, and more developed regulatory compliance and quality control systems. In the U.S. market, physicians prefer IOLs made out of acrylic. Acrylic IOLs currently account for a 72% share of the U.S. IOL market. We believe that we are positioned to compete effectively in the advanced material market segment with the Collamer IOL. We recently introduced an enhanced aspheric Collamer IOL and expect to introduce improved injectors in 2008 that we believe can strengthen our position and help reverse the decline in our overall IOL market share. Although the market for silicone IOLs, which currently account for 24% of the U.S. market, has declined in recent years, we believe they still provide an opportunity for us as we introduce improvements in silicone IOL technology and build market awareness of our Collamer IOLs and improved injection systems. Our ICL faces significant competition in the marketplace from other products and procedures that improve or correct refractive conditions, such as corrective eyeglasses, external contact lenses, and conventional and laser refractive surgical procedures. These products and procedures are long established in the marketplace and familiar to patients in need of refractive correction. In particular, eyeglasses and external contact lenses are much cheaper in the short term and more easily obtained, because a prescription for the product is usually written following a routine eye examination in a doctor’s office, without admitting the patient to a hospital or surgery center. We believe that the following providers of laser surgical procedures comprise our primary competition in the marketplace for patients seeking surgery to correct refractive conditions: Advanced Medical Optics (AMO), Alcon, Bausch & Lomb, and Nidek. All of these companies market Excimer lasers for corneal refractive surgery. Approval of custom ablation, along with the addition of wavefront technology, has increased awareness of corneal refractive surgery by patients and practitioners. In the phakic implant market, there are only two approved phakic IOLs available in the U.S., our VisianTM ICL and the AMO Verisyse. In international markets, our ICL’s main competition is the AMO Verisyse, which is also sold as the Ophtec Artisan IOL, although there are several other phakic IOLs, manufactured by various companies, which are also available. CompetitionCompetition in the ophthalmic surgical product market is intense and characterized by extensive research and development and rapid technological change. Development by competitors of new or improved products, processes or technologies may make our products obsolete or less competitive. Accordingly, we must devote continued efforts and significant financial resources to enhance our existing products and to develop new products for the ophthalmic industry. We believe our primary competitors in the development and sale of products used to surgically correct cataracts, specifically foldable IOLs, include Alcon Laboratories (“Alcon”), Advanced Medical Optics (“AMO”), and Bausch & Lomb. According to a 2007 Market Scope report, Alcon holds 55% of the U.S. IOL market, followed by AMO with 26% and Bausch & Lomb with 13%. We hold approximately 4% of the U.S. IOL market. Our competitors have been established for longer periods of time than we have and have significantly greater resources than we have, including greater name recognition, larger sales operations, greater ability to In the U.S. market, physicians prefer IOLs made out of acrylic. Acrylic IOLs currently account for a 72% share of the U.S. IOL market. We believe that we are positioned to compete effectively in the advanced material market segment with the Collamer IOL. We recently introduced an enhanced aspheric Collamer IOL and expect to introduce improved injectors in 2008 that we believe can strengthen our position and help reverse the decline in our overall IOL market share. Although the market for silicone IOLs, which currently account for 24% of the U.S. market, has declined in recent years, we believe they still provide an opportunity for us as we introduce Our ICL faces significant competition in the marketplace from other products and procedures that improve or correct refractive conditions, such as corrective eyeglasses, external contact lenses, and conventional and laser refractive surgical procedures. These products and procedures are long established in the marketplace and familiar to patients in need of refractive correction. In particular, eyeglasses and external contact lenses are much cheaper in the short term and more easily obtained, because a prescription for the product is usually written following a routine eye examination in a doctor’s office, without admitting the patient to a We believe that the following providers of laser surgical procedures comprise our primary competition in the marketplace for patients seeking surgery to correct refractive conditions: Advanced Medical Optics (AMO), Alcon, Bausch & Lomb, and Nidek. All of these companies market Excimer lasers for corneal refractive surgery. Approval of custom ablation, along with the addition of wavefront technology, has increased awareness of corneal refractive surgery by patients and practitioners. In the phakic implant market, there are only two approved phakic IOLs available in the U.S., our VisianTM ICL and the AMO Verisyse. In international These excerpts taken from the STAA 10-K filed Feb 7, 2008. Competition
Competition in the ophthalmic surgical product market is intense
and characterized by extensive research and development and
rapid technological change. Development by competitors of new or
improved products, processes or technologies may make our
products obsolete or less competitive. Accordingly, we must
devote continued efforts and significant financial resources to
enhance our existing products and to develop new products for
the ophthalmic industry.
We believe our primary competitors in the development and sale
of products used to surgically correct cataracts, specifically
foldable IOLs and phacoemulsification machines, include Alcon
Laboratories (“Alcon”), Advanced Medical Optics
(“AMO”), and Bausch & Lomb. According to a
2006 Market Scope report, Alcon holds 54% of the U.S. IOL
market, followed by AMO with 26% and Bausch & Lomb
with 14%. We hold approximately 4% of the U.S. IOL market.
Our competitors have been established for longer periods of time
than we have and have significantly greater resources than we
have, including greater name recognition, larger sales
operations, greater ability to finance research and development
and proceedings for regulatory approval, and more developed
regulatory compliance and quality control systems.
In the U.S. market, physicians prefer IOLs made out of
acrylic. Acrylic IOLs currently account for a 62% share of the
U.S. IOL market. We believe that we are positioned to
compete effectively in the advanced material market segment with
the Collamer IOL. We plan to introduce enhanced models of the
Collamer IOL and improved injectors which we believe can
strengthen our position and help reverse the decline in our
overall IOL market share. Although the market for Silicone IOLs,
which currently account for 34% of the U.S. market, has
declined in recent years, we
Table of Contents
believe they still provide an opportunity for us as we introduce
improvements in silicone IOL technology and build market
awareness of our Collamer IOLs and improved injection systems.
Our ICL faces significant competition in the marketplace from
other products and procedures that improve or correct refractive
conditions, such as corrective eyeglasses, external contact
lenses, and conventional and laser refractive surgical
procedures. These products and procedures are long established
in the marketplace and familiar to patients in need of
refractive correction. In particular, eyeglasses and external
contact lenses are much cheaper and more easily obtained,
because a prescription for the product is usually written
following a routine eye examination in a doctor’s office,
without admitting the patient to a hospital or surgery center.
We believe that the following providers of laser surgical
procedures comprise our primary competition in the marketplace
for patients seeking surgery to correct refractive conditions:
Advanced Medical Optics (AMO), Alcon, Bausch & Lomb,
Nidek and Wave Light. All of these companies market Excimer
lasers for corneal refractive surgery. Approval of custom
ablation, along with the addition of wavefront technology, has
increased awareness of corneal refractive surgery by patients
and practitioners. Conductive Keratoplasty (CK) by Refractec
competes for the hyperopic market for +.75 to +3.0 diopters. In
the phakic implant market, there are only two approved phakic
IOLs available in the U.S., our
Visiantm
ICL and the AMO Verisye. In international markets, our
ICL’s main competition is the Ophtec Artisan IOL, although
there are several other phakic IOLs, manufactured by various
companies, which are also available.
Competition Competition in the ophthalmic surgical product market is intense and characterized by extensive research and development and rapid technological change. Development by competitors of new or improved products, processes or technologies may make our products obsolete or less competitive. Accordingly, we must devote continued efforts and significant financial resources to enhance our existing products and to develop new products for the ophthalmic industry. We believe our primary competitors in the development and sale of products used to surgically correct cataracts, specifically foldable IOLs and phacoemulsification machines, include Alcon Laboratories (“Alcon”), Advanced Medical Optics (“AMO”), and Bausch & Lomb. According to a 2006 Market Scope report, Alcon holds 54% of the U.S. IOL market, followed by AMO with 26% and Bausch & Lomb with 14%. We hold approximately 4% of the U.S. IOL market. Our competitors have been established for longer periods of time than we have and have significantly greater resources than we have, including greater name recognition, larger sales operations, greater ability to finance research and development and proceedings for regulatory approval, and more developed regulatory compliance and quality control systems. In the U.S. market, physicians prefer IOLs made out of acrylic. Acrylic IOLs currently account for a 62% share of the U.S. IOL market. We believe that we are positioned to compete effectively in the advanced material market segment with the Collamer IOL. We plan to introduce enhanced models of the Collamer IOL and improved injectors which we believe can strengthen our position and help reverse the decline in our overall IOL market share. Although the market for Silicone IOLs, which currently account for 34% of the U.S. market, has declined in recent years, we
Table of Contentsbelieve they still provide an opportunity for us as we introduce improvements in silicone IOL technology and build market awareness of our Collamer IOLs and improved injection systems. Our ICL faces significant competition in the marketplace from other products and procedures that improve or correct refractive conditions, such as corrective eyeglasses, external contact lenses, and conventional and laser refractive surgical procedures. These products and procedures are long established in the marketplace and familiar to patients in need of refractive correction. In particular, eyeglasses and external contact lenses are much cheaper and more easily obtained, because a prescription for the product is usually written following a routine eye examination in a doctor’s office, without admitting the patient to a hospital or surgery center. We believe that the following providers of laser surgical procedures comprise our primary competition in the marketplace for patients seeking surgery to correct refractive conditions: Advanced Medical Optics (AMO), Alcon, Bausch & Lomb, Nidek and Wave Light. All of these companies market Excimer lasers for corneal refractive surgery. Approval of custom ablation, along with the addition of wavefront technology, has increased awareness of corneal refractive surgery by patients and practitioners. Conductive Keratoplasty (CK) by Refractec competes for the hyperopic market for +.75 to +3.0 diopters. In the phakic implant market, there are only two approved phakic IOLs available in the U.S., our Visiantm ICL and the AMO Verisye. In international markets, our ICL’s main competition is the Ophtec Artisan IOL, although there are several other phakic IOLs, manufactured by various companies, which are also available. This excerpt taken from the STAA 8-K filed Apr 26, 2007. Competition
Competition in the ophthalmic surgical product market is intense
and characterized by extensive research and development and
rapid technological change. Development by competitors of new or
improved products, processes or technologies may make our
products obsolete or less competitive. Accordingly, we must
devote continued efforts and significant financial resources to
enhance our existing products and to develop new products for
the ophthalmic industry.
We believe our primary competitors in the development and sale
of products used to surgically correct cataracts, specifically
foldable IOLs and phacoemulsification machines, include Alcon
Laboratories, Advanced Medical Optics, and Bausch &
Lomb. According to a 2006 Market Scope report, Alcon holds 54%
of the U.S. IOL market, followed by AMO with 26% and
Bausch & Lomb with 14%. We hold approximately 4% of the
U.S. IOL market. Our competitors have been established
longer than we have and have significantly greater resources
than we have, including greater name recognition, larger sales
operations, greater ability to finance research and development
and proceedings for regulatory approval, and more developed
regulatory compliance and quality control systems.
In the U.S. market, physicians prefer IOLs made out of
acrylic. Acrylic IOLs currently account for a 62% share of the
U.S. IOL market. We believe that we are positioned to
compete effectively in the advanced material market segment with
the Collamer IOL. We plan to introduce enhanced models of the
Collamer IOL and improved injectors which we believe can
strengthen our position and help reverse the decline in our
overall IOL market share. Although the market for silicone IOLs,
which currently account for 34% of the U.S. market, has
declined in recent years, we believe they still provide an
opportunity for us as we introduce improvements in silicone IOL
technology and build market awareness of our Collamer IOLs and
improved injection systems.
Our ICL faces significant competition in the marketplace from
other products and procedures that improve or correct refractive
conditions, such as corrective eyeglasses, external contact
lenses, and conventional and laser refractive surgical
procedures. These products and procedures are long established
in the marketplace and familiar to patients in need of
refractive correction. In particular, eyeglasses and external
contact lenses are much cheaper and more easily obtained,
because a prescription for the product is usually written
following a routine eye examination in a doctor’s office,
without admitting the patient to a hospital or surgery center.
We believe that the following providers of laser surgical
procedures are our primary competition in the marketplace for
patients seeking surgery to correct refractive conditions:
Advanced Medical Optics, Alcon, Bausch & Lomb, Nidek
and Wave Light. All of these companies market Excimer lasers for
corneal refractive surgery. Approval of custom ablation, along
with the addition of wavefront technology, has increased
awareness of corneal refractive surgery by patients and
practitioners. Conductive Keratoplasty (CK) by Refractec
competes for the hyperopic market for +.75 to +3.0 diopters. In
the phakic implant market, there are only two approved phakic
IOLs available in the U.S., our
Visiantm
ICL and the AMO Verisyse. In international markets, our
ICL’s main competition is the Ophtec Artisan IOL, although
several other phakic IOLs, manufactured by various companies,
are also available.
This excerpt taken from the STAA 10-K filed Mar 29, 2007. Competition
Competition in the ophthalmic surgical product market is intense
and characterized by extensive research and development and
rapid technological change. Development by competitors of new or
improved products, processes or technologies may make our
products obsolete or less competitive. Accordingly, we must
devote continued efforts and significant financial resources to
enhance our existing products and to develop new products for
the ophthalmic industry.
We believe our primary competitors in the development and sale
of products used to surgically correct cataracts, specifically
foldable IOLs and phacoemulsification machines, include Alcon
Laboratories (“Alcon”), Advanced Medical Optics
(“AMO”), and Bausch & Lomb. According to a
2006 Market Scope report, Alcon holds 54% of the U.S. IOL
market, followed by AMO with 26% and Bausch & Lomb with
14%. We hold approximately 4% of the U.S. IOL market. Our
competitors have been established for longer periods of time
than we have and have significantly greater resources than we
have, including greater name recognition, larger sales
operations, greater ability to finance research and development
and proceedings for regulatory approval, and more developed
regulatory compliance and quality control systems.
In the U.S. market, physicians prefer IOLs made out of
acrylic. Acrylic IOLs currently account for a 62% share of the
U.S. IOL market. We believe that we are positioned to
compete effectively in the advanced material market segment with
the Collamer IOL. We plan to introduce enhanced models of the
Collamer IOL and improved injectors which we believe can
strengthen our position and help reverse the decline in our
overall IOL market share. Although the market for Silicone IOLs,
which currently account for 34% of the U.S. market, has
declined in recent years, we
Table of Contents
believe they still provide an opportunity for us as we introduce
improvements in silicone IOL technology and build market
awareness of our Collamer IOLs and improved injection systems.
Our ICL faces significant competition in the marketplace from
other products and procedures that improve or correct refractive
conditions, such as corrective eyeglasses, external contact
lenses, and conventional and laser refractive surgical
procedures. These products and procedures are long established
in the marketplace and familiar to patients in need of
refractive correction. In particular, eyeglasses and external
contact lenses are much cheaper and more easily obtained,
because a prescription for the product is usually written
following a routine eye examination in a doctor’s office,
without admitting the patient to a hospital or surgery center.
We believe that the following providers of laser surgical
procedures comprise our primary competition in the marketplace
for patients seeking surgery to correct refractive conditions:
Advanced Medical Optics (AMO), Alcon, Bausch & Lomb,
Nidek and Wave Light. All of these companies market Excimer
lasers for corneal refractive surgery. Approval of custom
ablation, along with the addition of wavefront technology, has
increased awareness of corneal refractive surgery by patients
and practitioners. Conductive Keratoplasty (CK) by Refractec
competes for the hyperopic market for +.75 to +3.0 diopters. In
the phakic implant market, there are only two approved phakic
IOLs available in the U.S., our
Visiantm
ICL and the AMO Verisye. In international markets, our
ICL’s main competition is the Ophtec Artisan IOL, although
there are several other phakic IOLs, manufactured by various
companies, which are also available.
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for STAA: |
| |||||||
